The 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) is taking place in London, United Kindom from September 14-17, 2016
Neuro News Roundup: Potential MS Therapies
Three new multiple sclerosis studies show the promise of two drugs, amiselimod and alemtuzumab, as treatments and one, arbaclofen, for spasticity.
Interesting Neuro: ECTRIMS News & Alzheimer Marker
Our Sept. news includes a possible clinical marker and therapy target in Alzheimer disease and MS findings from an optical coherence tomography study.
ECTRIMS 2016: Managing MS Symptoms
Research presented at this ECTRIMS session covered management of multiple sclerosis-related fatigue, cognitive issues, and gait impairment.
New Imaging Techniques: MS Neuroprotection & Repair
This ECTRIMS session includes studies using 7T and 3T MRI images and translocator protein PET scans, as well as phenotypes in gray matter and more.
Early Relapsing-Remitting MS: Induction vs Escalation
Hot Topics session at ECTRIMS 2016: treat early active RRMS with potent induction therapy or immunomodulation then escalation? Where do you stand?
ECTRIMS 2016: Young MS Investigators’ Research
The session featured a study comparing MRI criteria for diagnosing MS, the role of spinal cord volume loss in predicting disease activity, and more.